5-HT1F Receptor Agonists: A New Treatment Option for Migraine Attacks?

Neurotherapeutics

Volumn 7, Issue 2, 2010, Pages 176-182

  Neeb, Lars ^a   Meents, Jannis ^a   Reuter, Uwe ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

5 HT1F; migraine; serotonin receptor; treatment; triptans

Indexed keywords

5 (4 FLUOROBENZAMIDO) 3 (1 METHYL 4 PIPERIDINYL) 1H INDOLE FUMARATE; CALCITONIN GENE RELATED PEPTIDE; COL 144; DIHYDROERGOTAMINE; FROVATRIPTAN; LY 306528; LY 397584; LY 573144; N (3 DIMETHYLAMINO 2,3,4,9 TETRAHYDRO 1H CARBAZOL 6 YL) 4 FLUOROBENZAMIDE; N [4 [5 [3 (2 AMINOETHYL) 1H INDOL 5 YL] 1,2,4 OXADIAZOL 3 YL]BENZYL]METHANESULFONAMIDE; NARATRIPTAN; NEUROPEPTIDE; PLACEBO; PROTEIN C FOS; RIZATRIPTAN; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 1F RECEPTOR; SEROTONIN 1F RECEPTOR AGONIST; SEROTONIN AGONIST; SUBSTANCE P; SUMATRIPTAN; TRIPTAN DERIVATIVE; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

ANALGESIA; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHENIA; BLOOD BRAIN BARRIER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTINUOUS INFUSION; DIZZINESS; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG PENETRATION; DRUG TREATMENT FAILURE; HUMAN; HYPERALGESIA; INHIBITION KINETICS; MEDICAL DECISION MAKING; MEDICAL RESEARCH; MIGRAINE; NERVE CELL; NONHUMAN; PARESTHESIA; PRIORITY JOURNAL; PROTEIN SECRETION; RECEPTOR BINDING; SIGNAL TRANSDUCTION; SOMNOLENCE; TRIGEMINAL NERVE; VASOCONSTRICTION; WEAKNESS;

BENZAMIDES; GENE EXPRESSION REGULATION; HUMANS; INDOLES; MIGRAINE DISORDERS; NEUROGENIC INFLAMMATION; PROTO-ONCOGENE PROTEINS C-FOS; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; TRIGEMINAL NUCLEI; TRYPTAMINES;

EID: 77953276186     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2010.03.003     Document Type: Article

References (68)

1. Ferrari M.D., Goadsby P.J., Roon K.I., and Lipton R.B. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 22 (2002) 633-658
2. Diener H.C., and Limmroth V. Advances in pharmacological treatment of migraine. Expert Opin Investig Drugs 10 (2001) 1831-1845
3. Goadsby P.J. The pharmacology of headache. Prog Neurobiol 62 (2000) 509-525
4. Bouchelet I., Cohen Z., Case B., Seguela P., and Hamel E. Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. Mol Pharmacol 50 (1996) 219-223
5. Longmore J., Hargreaves R.J., Boulanger C.M., et al. Comparison of the vasoconstrictor properties of the 5-HT1D-receptor agonists rizatriptan (MK-462) and sumatriptan in human isolated coronary artery: outcome of two independent studies using different experimental protocols. Funct Neurol 12 (1997) 3-9
6. Hamel E., Fan E., Linville D., Ting V., Villemure J.G., and Chia L.S. Expression of mRNA for the serotonin 5-hydroxytryptamine1D beta receptor subtype in human and bovine cerebral arteries. Mol Pharmacol 44 (1993) 242-246
7. Nilsson T., Longmore J., Shaw D., Olesen I.J., and Edvinsson L. Contractile 5-HT1B receptors in human cerebral arteries: pharmacological characterization and localization with immunocytochemistry. Br J Pharmacol 128 (1999) 1133-1140
8. Cohen Z., Bouchelet I., Olivier A., et al. Multiple microvascular and astroglial 5-hydroxytryptamine receptor subtypes in human brain: molecular and pharmacologic characterization. J Cereb Blood Flow Metab 19 (1999) 908-917
9. Longmore J., Razzaque Z., Shaw D., et al. Comparison of the vasoconstrictor effects of rizatriptan and sumatriptan in human isolated cranial arteries: immunohistological demonstration of the involvement of 5-HT1B-receptors. Br J Clin Pharmacol 46 (1998) 577-582
10. Connor H.E., Feniuk W., and Humphrey P.P. 5-Hydroxytryptamine contracts human coronary arteries predominantly via 5-HT2 receptor activation. Eur J Pharmacol 161 (1989) 91-94
11. Maassen vanDenBrink A., Reekers M., Bax W.A., Ferrari M.D., and Saxena P.R. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 98 (1998) 25-30
12. Cavazos J.E., Caress J.B., Chilukuri V.R., Devlin T., Gray L., and Hurwitz B.J. Sumatriptan-induced stroke in sagittal sinus thrombosis. Lancet 343 (1994) 1105-1106
13. Jayamaha J.E., and Street M.K. Fatal cerebellar infarction in a migraine sufferer whilst receiving sumatriptan. Intensive Care Med 21 (1995) 82-83
14. O'Connor P., and Gladstone P. Oral sumatriptan-associated transmural myocardial infarction. Neurology 45 (1995) 2274-2276
15. Mueller L., Gallagher R.M., and Ciervo C.A. Vasospasm-induced myocardial infarction with sumatriptan. Headache 36 (1996) 329-331
16. Abbrescia V.D., Pearlstein L., and Kotler M. Sumatriptan-associated myocardial infarction: report of case with attention to potential risk factors. J Am Osteopath Assoc 97 (1997) 162-164
17. Laine K., Raasakka T., Mantynen J., and Saukko P. Fatal cardiac arrhythmia after oral sumatriptan. Headache 39 (1999) 511-512
18. Bonaventure P., Voorn P., Luyten W.H., and Leysen J.E. 5HT1B and 5HT1D receptor mRNA differential co-localization with peptide mRNA in the guinea pig trigeminal ganglion. Neuroreport 9 (1998) 641-645
19. Rebeck G.W., Maynard K.I., Hyman B.T., and Moskowitz M.A. Selective 5-HT1D alpha serotonin receptor gene expression in trigeminal ganglia: implications for antimigraine drug development. Proc Natl Acad Sci U S A 91 (1994) 3666-3669
20. Smith D., Hill R.G., Edvinsson L., and Longmore J. An immunocytochemical investigation of human trigeminal nucleus caudalis: CGRP, substance P and 5-HT1D-receptor immunoreactivities are expressed by trigeminal sensory fibres. Cephalalgia 22 (2002) 424-431
21. Fanciullacci M., Alessandri M., Figini M., Geppetti P., and Michelacci S. Increase in plasma calcitonin gene-related peptide from the extracerebral circulation during nitroglycerin-induced cluster headache attack. Pain 60 (1995) 119-123
22. Goadsby P.J., Edvinsson L., and Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 28 (1990) 183-187
23. Juhasz G., Zsombok T., Modos E.A., et al. NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain 106 (2003) 461-470
24. Gomez-Mancilla B., Cutler N.R., Leibowitz M.T., et al. Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine. Cephalalgia 21 (2001) 727-732
25. Johnson K.W., Schaus J.M., Durkin M.M., et al. 5-HT1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs. Neuroreport 8 (1997) 2237-2240
26. Razzaque Z., Heald M.A., Pickard J.D., et al. Vasoconstriction in human isolated middle meningeal arteries: determining the contribution of 5-HT1b- and 5-HT1f-receptor activation. Br J Clin Pharmacol 47 (1999) 75-82
27. Adham N., Kao H.T., Schecter L.E., et al. Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci U S A 90 (1993) 408-412
28. Adham N., Borden L.A., Schechter L.E., et al. Cell-specific coupling of the cloned human 5-HT1F receptor to multiple signal transduction pathways. Naunyn Schmiedebergs Arch Pharmacol 348 (1993) 566-575
29. Waeber C., and Moskowitz M.A. [3H]sumatriptan labels both 5-HT1D and 5-HT1F receptor binding sites in the guinea pig brain: an autoradiographic study. Naunyn Schmiedebergs Arch Pharmacol 352 (1995) 263-275
30. Pascual J., del Arco C., Romón T., del Olmo E., Castro E., and Pazos A. Autoradiographic distribution of [3H]sumatriptan-binding sites in post-mortem human brain. Cephalalgia 16 (1996) 317-322
31. Bruinvels A.T., Landwehrmeyer B., Gustafson E.L., et al. Localization of 5-HT1B, 5-HT1D alpha, 5-HT1E and 5-HT1F receptor messenger RNA in rodent and primate brain. Neuropharmacology 33 (1994) 367-386
32. Hirst W.D., Cheung N.Y., Rattray M., Price G.W., and Wilkin G.P. Cultured astrocytes express messenger RNA for multiple serotonin receptor subtypes, without functional coupling of 5-HT1 receptor subtypes to adenylyl cyclase. Brain Res Mol Brain Res 61 (1998) 90-99
33. Bouchelet I., Case B., Olivier A., and Hamel E. No contractile effect for 5-HT1D and 5-HT1F receptor agonists in human and bovine cerebral arteries: similarity with human coronary artery. Br J Pharmacol 129 (2000) 501-508
34. Centurion D., Ortiz M.I., Sanchez-Lopez A., de Vries P., Saxena P.R., and Villalon C.M. Evidence for 5-HT(1B/1D) and 5-HT(2A) receptors mediating constriction of the canine internal carotid circulation. Br J Pharmacol 132 (2001) 983-990
35. Cohen M.L., and Schenck K. 5-Hydroxytryptamine(1F) receptors do not participate in vasoconstriction: lack of vasoconstriction to LY344864, a selective serotonin(1F) receptor agonist in rabbit saphenous vein. J Pharmacol Exp Ther 290 (1999) 935-939
36. Ma Q.P. Co-localization of 5-HT(1B/1D/1F) receptors and glutamate in trigeminal ganglia in rats. Neuroreport 12 (2001) 1589-1591
37. Moskowitz M.A., and Macfarlane R. Neurovascular and molecular mechanisms in migraine headaches. Cerebrovasc Brain Metab Rev 5 (1993) 159-177
38. Ramadan N.M. The link between glutamate and migraine. CNS Spectr 8 (2003) 446-449
39. Ferrari A., Spaccapelo L., Pinetti D., Tacchi R., and Bertolini A. Effective prophylactic treatments of migraine lower plasma glutamate levels. Cephalalgia 29 (2009) 423-429
40. Shepheard S., Edvinsson L., Cumberbatch M., et al. Possible antimigraine mechanisms of action of the 5HT1F receptor agonist LY334370. Cephalalgia 19 (1999) 851-858
41. Granados-Soto V., Arguelles C.F., Rocha-Gonzalez H.I., Godinez-Chaparro B., Flores-Murrieta F.J., and Villalon C.M. The role of peripheral 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E and 5-HT1F serotonergic receptors in the reduction of nociception in rats. Neuroscience 165 (2010) 561-568
42. Overshiner CC, Adham N, Zgombick JM, Branchek TA, Calligaro DO, Phebus LA. LY334370 is selective for the cloned 5-HT1f receptor. Paper presented at: 26th Annual Meeting of the Society for Neuroscience; 1996.
43. Phebus L.A., Johnson K.W., Zgombick J.M., et al. Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine. Life Sci 61 (1997) 2117-2126
44. Xu Y.C., Johnson K.W., Phebus L.A., et al. N-[3-(2-Dimethylaminoethyl)-2-methyl-1H-indol-5-yl]-4-fluorobenzamide: a potent, selective, and orally active 5-HT(1F) receptor agonist potentially useful for migraine therapy. J Med Chem 44 (2001) 4031-4034
45. Nelson D.L., Phebus L.A., Johnson K.W., Wainscott D.B., Cohen M.L., and Xu Y.C. COL-144: Preclinical profile of a selective 5-HT1F receptor agonist for migraine. Cephalalgia 29 (2009) 122-123
46. Markowitz S., Saito K., and Moskowitz M.A. Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain. J Neurosci 7 (1987) 4129-4136
47. Goldstein D.J., Offen W.W., Klein E.G., et al. Lanepitant, an NK-1 antagonist, in migraine prevention. Cephalalgia 21 (2001) 102-106
48. Peroutka S.J. Neurogenic inflammation and migraine: implications for the therapeutics. Mol Interv 5 (2005) 304-311
49. Wainscott D.B., Johnson K.W., Phebus L.A., Schaus J.M., and Nelson D.L. Human 5-HT1F receptor-stimulated [35S]GTPgammaS binding: correlation with inhibition of guinea pig dural plasma protein extravasation. Eur J Pharmacol 352 (1998) 117-124
50. Mitsikostas D.D., and Sanchez del Rio M. Receptor systems mediating c-fos expression within trigeminal nucleus caudalis in animal models of migraine. Brain Res Brain Res Rev 35 (2001) 20-35
51. Nozaki K., Moskowitz M.A., and Boccalini P. CP-93,129, sumatriptan, dihydroergotamine block c-fos expression within rat trigeminal nucleus caudalis caused by chemical stimulation of the meninges. Br J Pharmacol 106 (1992) 409-415
52. Mitsikostas D.D., Sanchez del Rio M., Moskowitz M.A., and Waeber C. Both 5-HT1B and 5-HT1F receptors modulate c-fos expression within rat trigeminal nucleus caudalis. Eur J Pharmacol 369 (1999) 271-277
53. Dixon C.M., Saynor D.A., Andrew P.D., Oxford J., Bradbury A., and Tarbit M.H. Disposition of sumatriptan in laboratory animals and humans. Drug Metab Dispos 21 (1993) 761-769
54. Edvinsson L., and Tfelt-Hansen P. The blood-brain barrier in migraine treatment. Cephalalgia 28 (2008) 1245-1258
55. Tfelt-Hansen P.C. Does sumatriptan cross the blood-brain barrier in animals and man?. J Headache Pain 11 (2010) 5-12
56. Katofiasc M., Johnson K.W., and Phebus L.A. The selective 5-HT1F agonists, LY334370 and LY397584, inhibit both central and peripheral branches of trigeminal sensory afferents in rats. Cephalalgia 20 (2000) 419-420
57. Shepheard S.L., Williamson D.J., Williams J., Hill R.G., and Hargreaves R.J. Comparison of the effects of sumatriptan and the NK1 antagonist CP-99,994 on plasma extravasation in Dura mater and c-fos mRNA expression in trigeminal nucleus caudalis of rats. Neuropharmacology 34 (1995) 255-261
58. Humphrey P.P., Feniuk W., Perren M.J., et al. GR43175, a selective agonist for the 5-HT1-like receptor in dog isolated saphenous vein. Br J Pharmacol 94 (1988) 1123-1132
59. Cohen M.L., Johnson K.W., Schenck K.W., and Phebus L.A. Migraine therapy: relationship between serotonergic contractile receptors in canine and rabbit saphenous veins to human cerebral and coronary arteries. Cephalalgia 17 (1997) 631-638
60. Ullmer C., Schmuck K., Kalkman H.O., and Lubbert H. Expression of serotonin receptor mRNAs in blood vessels. FEBS Lett 370 (1995) 215-221
61. Wurch T., Palmier C., Colpaert F.C., and Pauwels P.J. Recombinant saphenous vein 5-HT1B receptors of the rabbit: comparative pharmacology with human 5-HT1B receptors. Br J Pharmacol 120 (1997) 153-159
62. Bard J.A., Kucharewicz S.A., Zgombick J.M., Weinshank R.L., and Branchek T.A. Cloning and characterization of rabbit and dog 5-HFIF receptor subtypes: a comparison of the pharmacological profile to the human species homologue. Soc Neurosci Absts 22 (1996) 528.8(abstract)
63. Cohen M.L., and Schenck K. Contractile responses to sumatriptan and ergotamine in the rabbit saphenous vein: effect of selective 5-HT(1F) receptor agonists and PGF(2alpha). Br J Pharmacol 131 (2000) 562-568
64. Gossen D, de Surray JM, Onkelinx C. First human dose study with LY334370, a selective 5HT1f agonst. 12th Mgraine Trust International Symposium, 1998.
65. Goldstein D.J., Roon K.I., Offen W.W., et al. Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet 358 (2001) 1230-1234
66. Reuter U., Diener H.C., Färkkilä M., and Ferrari M. COL-144: a selective 5-HT1F agonist for the treatment of migraine attacks. Cephalalgia 29 (2009) 122
67. Pilgrim A.J., Dussault B., Rupniak N.M.J., White J., Mazur D., and DiSanto A.R. COL-144, an orally bioavailable selective 5-HT1F receptor agonist for acute migraine therapy. Cephalalgia 29 Suppl 1 (2009) 24-25
68. Ramadan N.M., Skljarevski V., Phebus L.A., and Johnson K.W. 5-HT1F receptor agonists in acute migraine treatment: a hypothesis. Cephalalgia 23 (2003) 776-785